Gilead, AbbVie rack up new payer deals, but hep C obstacles loom across the Atlantic

Tracy Staton

The hepatitis C market is breaking new ground all over the place. As payers put the squeeze on Sciences and for discounts in the U.S., England's National Health Service is delaying a broad rollout of Gilead's blockbuster Sovaldi till July, citing the drug's high cost–an unprecedented move on a treatment already blessed by the country's cost-effectiveness watchdogs.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS